Reflow Medical competitors

Mr. Ward has been a member of our Board of Directors since 2013 and has served as Chairman since November 2014. Mr. Ward served as our Interim President and Chief Executive Officer commencing in November 2015. In August 2016, Mr. Ward was appointed President and Chief Executive Officer. Since 2013, Mr. Ward has been one of the Managing Directors at SightLine Partners. Following his appointment as our President and Chief Executive Officer, Mr. Ward continues to be a Managing Director of Sightline Opportunity Management Fund II, LLC, and may provide limited advisory and consulting services to Sightline Partners in this capacity.

Shahriar Matin is a Chief Executive Officer at Cordis, Board Member at KORU Medical Systems, and Managing Director at Spectranetics International BV and is based in Colorado Springs, Colorado. He has worked as Senior VP:Operations at SPECTRANETICS CORP, Chief Operating Officer at ViewRay Inc., and Chief Operating Officer at SPECTRANETICS CORP. Shahriar studied at Harvard Business School between 2001 and 2003 and University of California - UC Berkeley between 1993 and 1997.

Bruce Shook is a medical device executive with more than 30 years of industry experience, including multiple early stage ventures focused on opportunities in cardiac surgery, cardiology, neurosurgery, psychiatry and vascular disease. He serves as Director, President and CEO for both Intact Vascular and Vesper Medical. Intact Vascular is a privately held medical technology company that develops and commercializes vascular scaffolding technology for the treatment of peripheral arterial disease. The company is currently marketing the Tack Endovascular System® in the U.S. and Europe. Vesper Medical was spun out of Intact Vascular in late 2016 and is developing a novel family of venous stents designed to treat deep venous disease. Prior to Intact Vascular and Vesper Medical, Mr. Shook was co-founder, Director, President and CEO of Neuronetics, Inc., [NASDAQ: STIM] a publicly traded device company that markets a non-invasive brain stimulation technology for the treatment of depression. Previously, Mr. Shook was co-founder, Director, President and CEO at Neuron Therapeutics, a venture-backed company developing a drug/device product for the treatment of CNS disorders, and President of Abiomed [NASDAQ: ABMD], where he obtained PMA approval for the first FDA-approved ventricular assist device. Mr. Shook also developed cardiac pacing and anti-arrhythmia products at Cordis Corporation. Mr. Shook holds advanced degrees in Biomedical Engineering and Business Administration from Columbia University and the MIT Sloan School of Management, respectively. He earned a B.S. degree in Chemical Engineering from Penn State University. Mr. Shook currently serves on the Board of Directors at Neuronetics, Venarum Medical, the Penn State Research Foundation (Vice Chairman) and Life Sciences Pennsylvania (Medical Technology Committee Chairman). He previously served on the Board of Directors at Surgiquest, Respicardia and CoTherix.

Dr. Schilling has 35 years of operating and general management experience in the medical device and technology industries, at Toshiba, Diasonics and General Electric. He was a director at Stentor at 2007 when it was sold to Philips. He also teaches business strategy at Stanford and serves on several corporate boards in the medical field. Dr. Schilling earned his B.SC. EE from City College of New York, his M.Sc. from Princeton University, and a Ph.D. from the Polytechnic Institute of New York University.